



SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Ref: SPL/CORP-SEC/2018-19/BSE/745

Dated: 05/06/2018

To,

Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

**Sub: Outcome of the Adjourned Board Meeting for the FY 2018-19
held on Tuesday 05TH June 2018 with Scrip Code 524703.**

A Meeting of the Board of Directors of the Company duly convened on **Tuesday, 05th June 2018 at 5:00 p.m. and Concluded at 7:35 p.m.** at the Corporate Office of the Company at Sandu Nagar, D K Sandu Marg, Chembur, Mumbai inter alia, discussed the following business:-

1. It has approved Audited Financial Results for the Quarter and year ended 31st March 2018 along with Independent Audit Report.
2. It has considered and Recommended Re appointment of Shri Umesh B. Sandu as the Managing Director w.e.f from 01st April 2018.
3. It has considered and recommended appointment of M/s Dileep and Prithvi, Chartered Accountant as Statutory Auditor of the Company.
4. It has approved appointment of CS Swapnil Dixit, Practising Company Secretary as the Secretarial Auditor for the FY 2018-19.
5. It has taken on record Declaration regarding Audit Report on Standalone Financial Results for the Quarter and Year ended 31st March 2018 with unmodified opinion signed by the Managing Director.

You are requested to kindly take the same on record.



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587





SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Thanking You

Yours Faithfully

For Sandu Pharmaceuticals Limited



Company Secretary



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587





SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Ref: SPL/Corp.sec/2018-19/746

Dated: 05/06/2018

To
BSE Ltd
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai 400 001

Scrip Code: 524703

Sub: Declaration regarding Audit Report on Standalone Financial Results for the Quarter and Year ended 31st March 2018 with unmodified opinion of the Independent Auditors.

Dear Sir,

We hereby confirm and declare that the Statutory Auditors of the Company i.e M/s Dileep and Prithvi, Chartered Accountants, Mumbai (Firm No:122290W), have issued the Audit Report on Standalone Financial Results of the Company for the Quarter and Year ended 31st March 2018 with Unmodified opinion.

We submit this declaration as required under the provisions of the Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) 2015 as amended and circular CIR/CFD/CMD/56/2016 May, 2016 issued by SEBI.

You are requested to take the above letter on record.

Yours Faithfully
For Sandu Pharmaceuticals Limited

Umesh B Sandu
Managing Director
DIN: 01132141



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587




STATEMENT OF ASSETS & LIABILITIES FOR THE HALF YEAR ENDED 31st MARCH, 2018

Sr no	Particulars	As at 31 st March	As at 31 st March	As at 1 st April
		2018	2017	2016
I	ASSETS			
	Non Current Assets			
	a)Property , plant & Equipment	1,741.07	1731.80	1762.29
	b)Other Intangible Assets	15.94	17.1	
	c)Financial Assets			
	i) Investments	112.39	99.15	78.64
	ii)Other Financial Assets			
	d)Other current assets			
	Total of non Current Assets	1,869.40	1848.05	1840.93
	a) Inventories	1,144.04	1067.83	1115.08
	b)Financial Asset			
	i) Investments			
	ii) Trade Receivables	669.39	634.69	714.73
	iii) cash & Cash Equivalents	140.78	268.69	69.42
	iv) Bank & other Cash Equivalents			
	v) Loans			
	vi)Other Financial Assets	623.65	820.14	1292.54
	c) Other Current Assets	5.45	3.80	5.29
	Total of Curent Assets	2,583.32	2795.15	3197.06
	TOTAL ASSETS	4,452.72	4,643.20	5,037.98
	EQUITY & LIABILITIES			
	a) Equity Share Capital	708.10	708.10	708.1
	b)Other Equity	2,100.15	2032.67	2057.67
	Total Equity	2,808.25	2740.77	2765.77
II	LIABILITIES			
	Non -Current Liabilities			
	a)Financial liabilities			
	i) Borrowings	24.65	8.93	77.82
	ii)Other Financial Liabilities			
	b) Proviions	81.57	79.85	92.82
	Total Non current Liabilities	106.22	88.78	170.64
	Current Liability			
	a)Financial liabilities			
	i) Borrowings	910.84	992.78	1005.22
	ii) Trade Payables	302.20	408.66	587.64
	iii)other financial Liabilities			
	b) Other Current Liabilities	114.63	147.92	190.15
	c) Provisions	210.57	264.29	318.56
	Total current Liabilities	1,538.24	1813.65	2101.57
	Total Liabilites	4,452.71	4643.20	5037.98

For Sandu Pharmaceuticals Ltd

Umesh Sandu
Director

Date :- 05/06/2018



Regd. & Factory Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, Fax: +91 832 2407008, E-mail: sandupharma@sandu.in

CIN:L24233GA1985PLC001587

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2018						
(Rs in Lakhs)						
Particulars	Quarter ended			Year Ended		
	March 31 st,2018	December 31 st,2017	March 31st ,2017	March 31st,2018	March 31st,2017	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
Income						
1) a) Revenue from Operations	1222.71	1,438.70	1,062.34	4,915.99	4,367.10	
b) Other Income	8.40	0.84	2.01	12.18	39.17	
Total income	1231.11	1,439.54	1,064.35	4,928.17	4,406.27	
2) Expenses						
a) Cost of materials Consumed	258.45	215.00	191.36	741.93	746.08	
b) Purchases of Stock in Trade	575.01	713.57	529.72	2,188.82	1,736.36	
c) Changes in Inventories work in progress & stock in Trade	(88.54)	(130.71)	(50.28)	(91.38)	81.22	
d) Excise on Sales of goods				14.40	84.58	
e) Employee Benefit Expenses	197.67	144.47	153.39	593.64	541.80	
f) Finance costs	28.20	30.43	32.00	123.10	149.41	
g) Depreciation & amortisation Expenses	23.75	12.59	21.80	60.24	86.76	
h) Other Expenses	196.21	399.73	296.85	1,221.90	984.00	
Total Expenses	1,190.75	1,385.08	1,174.84	4,852.65	4,410.21	
Profit / Loss before Exceptional items & Tax (1-2)	40.36	54.46	(110.49)	75.52	(3.94)	
Exceptional items			(9.28)		(9.28)	
3) Profit / (Loss) Before Tax (3-4)	40.36	54.46	(101.21)	75.52	5.33	
4) Current Tax	10.39	16.39	8.69	19.78	65.99	
Deferred Tax				(0.41)	(16.24)	
5) Profit / (Loss) After Tax	29.97	38.07	(109.90)	56.15	(44.42)	
Other Comprehensive Income that: Will not be reclassified to Profit & Loss	(8.79)	9.15	7.45	13.44	22.69	
That will be reclassified to Profit & Loss						
Tax on Other Comprehensive Income				-2.12	(3.28)	
Total Other Comprehensive Income	(8.79)	9.15	7.45	11.32	19.41	
Total Comprehensive Income for the period	21.18	47.22	(102.45)	67.47	(25.01)	
Paid up Equity share Capital (Face Value of Rs 10 /-per share	708.10	708.10	708.10	708.10	708.10	
6) Earnings per share of Rs 10 /-each Not annualised) Rs						
a) Basic	0.42	0.54	(1.55)	0.79	(0.63)	
b) Diluted						

Annexure A			
		For Quarter Ended 31st March-17	Year Ended 31 st March-17
Net profit/loss after tax as per previous GAAP (Indian GAAP)		20.35	42.37
Other adjustments		130.25	86.79
Net profit/loss after tax before OCI as per IndAS		-109.9	(44.42)
Other Comprehensive Income		7.45	19.41
Total Comprehensive Income as per IndAS		(102.45)	(25.01)

For Sandu Pharmaceuticals Ltd

Umesh Sandu
Director

Date: 05/06/2018

Regd. & Factory Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, Fax: +91 832 2407008, E-mail: sandupharma@sandu.in


CIN:L24233GA1985PLC001587

1. The audited Standalone and consolidated financial results of the company for the year ended March 31, 2018 have been reviewed by the audit committee of the Board and approved by the Board of Directors at the meeting held on 30th May 018 which was further adjourned to 5th June ,2018.
- 2 The company has adopted Indian Accounting Standards ("Ind AS") from 1st April 2017 And accordingly results for the quarter ended and year ended March 31, 2018 are in Compliance with Indian Accounting Standards (Ind AS) notified by the ministry of Corporate affairs as prescribed under section 133 of the Companies Act, 2013 & Other accounting principles generally accepted in India.
- 3 The reconciliation of Net Profit for the quarter and year ended 31st March , 2018 in accordance with India GAAP to total comprehensive income in accordance with Ind AS financials is as per **Annexure A**.
- 4 Consequent to the introduction of Goods and Service Tax Act (GST) wef 1st July 2017, Central Excise, Value Added Tax (VAT), etc have been subsumed into GST in Accordance with India Accounting Standards 18 on revenue and schedule III of the companies Act 2013 unlike Excise duties, levies like GST; VAT etc. are not part of Revenue. Accordingly, the figure for the quarter & year ended 31st March 2018 are not comparable with the corresponding period / previous year presented results.
- 5 Previous period's figures have been regrouped whenever necessary.



Date :- 05/06/2018

For Sandu Pharmaceuticals Ltd



Umesh Sandu
Director



Auditor's Report on Quarterly and Annual Standalone Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors,
Sandu Pharmaceuticals Limited
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.

1. We have audited the accompanying Standalone Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter and year ended March 31, 2018 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. These quarterly and annual standalone financial results have been prepared on the basis of the standalone financial statements, which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these standalone financial results based on our audit of such standalone financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India. Attention is drawn to the fact that the figures for the quarters ended March 31, as reported in these results are the balancing figures between audited figures in respect of the years ended March 31, and the published year to date figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe our audit provides a reasonable basis for our opinion.
3. The Standalone Financial Results for the quarter and year ended March 31, 2017, included in the Statement, are based on the previously issued Standalone Financial Results of the Company, prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 ('previous GAAP'). Management has adjusted these standalone results for the differences in accounting principles adopted by the Company on transition to the Indian Accounting Standards ('Ind AS') and presented reconciliations of the profit and equity under Ind AS of the year ended March 31, 2017 with the profit reported under the previous GAAP, which have been approved by the Company's Board of Directors and audited by us.



4. In our opinion and to the best of our information and according to the explanations given to us, these quarterly as well as year to date financial results:
- are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, in this regard; and
 - give a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the profit, total comprehensive income and other financial information for the quarter and year ended March 31, 2018.

The statement includes the results for the quarter ended 31st March, 2018 being the balancing figure between audited figures in respect of the full financial year and the unaudited year to date figures up to third quarter of the current financial year.

For Dileep & Prithvi

Chartered Accountants

Firm Registration Number : 122290W

Dileepkumar Shah

(Partner)

Membership Number : 046848



Place : Mumbai

Date : 30th May, 2018